SEARCH

SEARCH BY CITATION

References

  • 1
    Strzelczyk JJ, Dignan MB. Disparities in adherence to recommended followup on screening mammography: interaction of sociodemographic factors. Ethn Dis. 2002; 12: 77-86.
  • 2
    Gwyn K, Bondy ML, Cohen DS, et al. Racial differences in diagnosis, treatment, and clinical delays in a population-based study of patients with newly diagnosed breast carcinoma. Cancer. 2004; 100: 1595-1604.
  • 3
    Center to Reduce Cancer Health Disparities. Economic Costs of Cancer Health Disparities. Bethesda, Md: National Cancer Institute, National Institute of Health; 2007.
  • 4
    Lurie JD, Welch HG. Diagnostic testing following fecal occult blood screening in the elderly. J Natl Cancer Inst. 1999; 91: 1641-1646.
  • 5
    Baig N, Myers RE, Turner BJ, et al. Physician-reported reasons for limited follow-up of patients with a positive fecal occult blood test screening result. Am J Gastroenterol. 2003; 98: 2078-2081.
    Direct Link:
  • 6
    Bickell NA, Wang JJ, Oluwole S, et al. Missed opportunities: racial disparities in adjuvant breast cancer treatment. J Clin Oncol. 2006; 24: 1357-1362.
  • 7
    Griggs JJ, Sorbero ME, Stark AT, Heininger SE, Dick AW. Racial disparity in the dose and dose intensity of breast cancer adjuvant chemotherapy. Breast Cancer Res Treat. 2003; 81: 21-31.
  • 8
    Shavers VL, Harlan LC, Stevens JL. Racial/ethnic variation in clinical presentation, treatment, and survival among breast cancer patients under age 35. Cancer. 2003; 97: 134-147.
  • 9
    Freeman HP, Muth BJ, Kerner JF. Expanding access to cancer screening and clinical follow-up among the medically underserved. Cancer Pract. 1995; 3: 19-30.
  • 10
    Center to Reduce Cancer Health Disparities. Patient Navigation Research Program (PNRP) Overview. 2007. Available at: http://crchd.cancer.gov/pnp/pnrp-overview.html Accessed April 11, 2007.
  • 11
    Psooy BJ, Schreuer D, Borgaonkar J, Caines JS. Patient navigation: improving timeliness in the diagnosis of breast abnormalities. Can Assoc Radiol J. 2004; 55: 145-150.
  • 12
    Farber JM, Deschamps M, Cameron R. Investigation and Assessment of the “Navigator Role” in Meeting the Information, Decisional and Educational Needs of Women with Breast Cancer in Canada. Ottawa, Ontario, Canada: Canadian Breast Cancer Initiative, Health Canada, 2002.
  • 13
    Battaglia TA, Roloff K, Posner MA, Freund KM. Improving follow-up to abnormal breast cancer screening in an urban population. A patient navigation intervention. Cancer. 2007; 109( 2 suppl): 359-367.
  • 14
    Wells KJ, Battaglia TA, Dudley DJ, et al. Patient navigation: state of the art or is it science? Cancer. 2008; 113: 1999-2010.
  • 15
    Freeman HP. Patient navigation: a community centered approach to reducing cancer mortality. J Cancer Educ. 2006; 21( 1 suppl): S11-S14.
  • 16
    Freeman HP, Wasfie TJ. Cancer of the breast in poor black women. Cancer. 1989; 63: 2562-2569.
  • 17
    Oluwole SF, Ali AO, Adu A, et al. Impact of a cancer screening program on breast cancer stage at diagnosis in a medically underserved urban community. J Am Coll Surg. 2003; 196: 180-188.
  • 18
    Centers for Medicare and Medicaid Services, the Schneider Institute for Health Policy, and the Heller School for Social Policy and Management. Evidence Report and Evidence Based Recommendations: Cancer Prevention and Treatment Demonstration for Ethnic and Racial Minorities. Waltham, Mass: Brandeis University; 2003.
  • 19
    Smedley BD, Stith AY, Nelson AR. Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. Washington, DC: National Academy Press; 2002.
  • 20
    Weinrich SP, Boyd MD, Weinrich M, Greene F, Reynolds WA Jr, Metlin C. Increasing prostate cancer screening in African American men with peer-educator and client-navigator interventions. J Cancer Educ. 1998; 13: 213-219.
  • 21
    Freeman HP, Chu KC. Determinants of cancer disparities: barriers to cancer screening, diagnosis, and treatment. Surg Oncol Clin N Am. 2005; 14: 655-669.
  • 22
    Dohan D, Schrag D. Using navigators to improve care of underserved patients: current practices and approaches. Cancer. 2005; 104: 848-855.
  • 23
    Christie J, Itzkowitz S, Lihau-Nkanza I, Castillo A, Redd W, Jandorf L. A randomized controlled trial using patient navigation to increase colonoscopy screening among low-income minorities. J Natl Med Assoc. 2008; 100: 278-284.
  • 24
    Ferrante JM, Chen PH, Kim S. The effect of patient navigation on time to diagnosis, anxiety, and satisfaction in urban minority women with abnormal mammograms: a randomized controlled trial. J Urban Health. 2008; 85: 114-124.
  • 25
    Ell K, Vourlekis B, Lee PJ, Xie B. Patient navigation and case management following an abnormal mammogram: a randomized clinical trial. Prev Med. 2007; 44: 26-33.
  • 26
    Braithwaite RS, Meltzer DO, King JT Jr, Leslie D, Roberts MS. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care. 2008; 46: 349-356.
  • 27
    Gold MR, Siegal JE, Russel LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
  • 28
    Freund KM, Battaglia TA, Calhoun E, et al. National Cancer Institute Patient Navigation Research Program: methods, protocol, and measures. Cancer. 2008; 113: 3391-3399.
  • 29
    Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA. 1996; 276: 1253-1258.
  • 30
    The EuroQol Group. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy. 1990; 16: 199-208.
  • 31
    Earle CC, Chapman RH, Baker CS, et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol. 2000; 18: 3302-3317.
  • 32
    Du XL, Fang S, Coker AL, et al. Racial disparity and socioeconomic status in association with survival in older men with local/regional stage prostate carcinoma: findings from a large community-based cohort. Cancer. 2006; 106: 1276-1285.
  • 33
    Ward E, Jemal A, Cokkinides V, et al. Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin. 2004; 54: 78-93.
  • 34
    Mandelblatt JS, Cullen J, Lawrence WF, et al. Economic evaluation alongside a clinical trial of psycho-educational interventions to improve adjustment to survivorship among patients with breast cancer. J Clin Oncol. 2008; 26: 1684-1690.
  • 35
    Polsky D, Mandelblatt JS, Weeks JC, et al. Economic evaluation of breast cancer treatment: considering the value of patient choice. J Clin Oncol. 2003; 21: 1139-1146.
  • 36
    Mauskopf JA, Paul JE, Grant DM, Stergachis A. The role of cost-consequence analysis in healthcare decision-making. Pharmacoeconomics. 1998; 13: 277-288.
  • 37
    Yabroff KR, Lamont EB, Mariotto A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst. 2008; 100: 630-641.
  • 38
    Yabroff KR, Davis WW, Lamont EB, et al. Patient time costs associated with cancer care. J Natl Cancer Inst. 2007; 99: 14-23.
  • 39
    Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics. 2000; 17: 479-500.
  • 40
    Mandelblatt J, Freeman H, Winczewski D, et al. The costs and effects of cervical and breast cancer screening in a public hospital emergency room. The Cancer Control Center of Harlem. Am J Public Health. 1997; 87: 1182-1189.
  • 41
    Mandelblatt JS, Fryback DG, Weinstein MC, Russell LB, Gold MR. Assessing the effectiveness of health interventions for cost-effectiveness analysis. Panel on Cost-Effectiveness in Health and Medicine. J Gen Intern Med. 1997; 12: 551-558.
  • 42
    Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996; 276: 1172-1177.
  • 43
    Zhou X-HA, Ramsey SD. Assessing the equality of means of healthcare costs. Expert Rev Pharmacoecon Outcomes Res. 2003; 3: 561-567.